Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis

Arthritis and Rheumatism

Volumn 56, Issue 6, 2007, Pages 1894-1903

  Pitashny, Milena ^a   Schwartz, Noa ^a   Qing, Xiaoping ^a   Hojaili, Bernard ^a   Aranow, Cynthia ^b   Mackay, Meggan ^b   Putterman, Chaim ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; DAPSONE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LIPOCALIN; LIPOCALIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; ONCOPROTEIN;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BLOOD LEVEL; CAUCASIAN; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNICITY; FEMALE; HISPANIC; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MESANGIUM CELL; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX; STATISTICAL ANALYSIS; URINE LEVEL; WESTERN BLOTTING; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ETHNOLOGY; HOSPITALIZATION; KIDNEY; PATHOPHYSIOLOGY; RISK FACTOR; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE;

ACUTE-PHASE PROTEINS; ADULT; AFRICAN AMERICANS; AGE FACTORS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 34447558312     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22594     Document Type: Article

References (43)

1. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD, for the Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000;35:904-14.
2. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol 1994;21:2046-51.
3. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
4. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68.
5. Blatt NB, Glick GD. Anti-DNA autoantibodies and systemic lupus erythematosus. Pharmacol Ther 1999;83:125-39.
6. Putterman C. New approaches to the renal pathogenicity of anti-DNA antibodies in systemic lupus erythematosus. Autoimmun Rev 2004;3:7-11.
7. Waldman M, Madaio MP. Pathogenic autoantibodies in lupus nephritis. Lupus 2005;14:19-24.
8. Shlomchik MJ, Madaio MP. The role of antibodies and B cells in the pathogenesis of lupus nephritis. Springer Semin Immunopathol 2003;24:363-75.
9. Qing X, Zavadil J, Crosby MB, Hogarth MP, Hahn BH, Mohan C, et al. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum 2006;54:2198-210.
10. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, et al. An iron delivery pathway mediated by a lipocalin. Mol Cell 2002;10:1045-56.
11. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997;45:17-23.
12. Xu SY, Pauksen K, Venge P. Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections. Scand J Clin Lab Invest 1995;55:125-31.
13. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996;38:414-20.
14. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-43.
15. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231-8.
16. Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J, et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006;21:856-63.
17. Trachtman H, Christen E, Cnaan A, Patrick J, Mai V, Mishra J, et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006;21:989-94.
18. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24:307-15.
19. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006;26:287-92.
20. Brunner HI, Mueller M, Rutherford C, Passo MH, Witte D, Grom A, et al. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus. Arthritis Rheum 2006;54:2577-84.
21. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
22. Farquhar MG. The glomerular basement membrane: not gone, just forgotten. J Clin Invest 2006;116:2090-3.
23. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432:917-21.
24. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998;316:504-9.
25. Churg J, Sonbin L. Classification and atlas of glomerular disease. Tokyo: Igaku-Shoin; 1982.
26. Gutierrez-Adrianzen OA, Koutouzov S, Mota RM, das Chagas Medeiros MM, Bach JF, de Holanda Campos H. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol 2006;33:1538-44.
27. Ka SM, Rifai A, Chen JH, Cheng CW, Shui HA, Lee HS, et al. Glomerular crescent-related biomarkers in a murine model of chronic graft versus host disease. Nephrol Dial Transplant 2006;21:288-98.
28. Alarcon GS, Calvo-Alen J, McGwin G Jr, Uribe AG, Toloza SM, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 2006;65:1168-74.
29. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability [review]. Arthritis Rheum 2004;50:1709-20.
30. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity [review]. Arthritis Rheum 2004;50:2048-65.
31. Merrill JT, Buyon JP. The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol 2005;19:709-26.
32. Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 2005;17:543-9.
33. Lefkowith JB, Gilkeson GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies [review]. Arthritis Rheum 1996;39:894-903.
34. Karp DR. Complement and systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:538-42.
35. Cross J, Jayne D. Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol 2005;19:785-98.
36. Hopper JE, Golbus J, Meyer C, Ferrer GA. Urine free light chains in SLE: clonal markers of B-cell activity and potential link to in vivo secreted Ig. J Clin Immunol 2000;20:123-37.
37. Bobkova I, Lysenko L, Polyantseva L, Tareyeva I. Urinary von Willebrand factor as a marker of lupus nephritis progression. Nephron 2001;87:369-70.
38. Molad Y, Miroshnik E, Sulkes J, Pitlik S, Weinberger A, Monselise Y. Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage. Clin Exp Rheumatol 2002;20:403-6.
39. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 1996;5:571-5.
40. Avihingsanon Y, Phumesin P, Benjachat T, Akkasilpa S, Kittikowit V, Praditpornsilpa K, et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006;69:747-53.
41. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005;16:467-73.
42. Tucci M, Barnes EV, Sobel ES, Croker BP, Segal MS, Reeves WH, et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum 2004;50:1842-9.
43. Chan RW, Lai FM, Li EK, Tarn LS, Wong TY, Szeto CY, et al. Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2004;50:2882-90.